Ask AI

CDK4/6 Inhibition in Breast Cancer: Expert Perspectives on Integrating Guideline Updates and Recent Advances Into Practice

Gain expert-informed strategies for incorporating CDK4/6 inhibitors into the treatment of patients with early or advanced/metastatic breast cancer according to current NCCN guidelines and managing treatment-related adverse events through a certified on-demand webcast, podcast, and accompanying downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner
ProCE Banner

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation